after joining the study, you will undergo baseline assessments that include a review of medical history, a physical examination, laboratory tests (blood and urine), and imaging studies to document the status of the solid tumor.

these assessments establish the starting point for safety monitoring and later comparison with treatment results.

the first treatment cycle begins with an intravenous infusion of ivonescimab. the infusion is performed in a clinical setting by trained staff.

depending on the protocol, additional intravenous agents may be given in the same visit, such as cetuximab, cisplatin, carboplatin or pemetrexed. each drug is delivered as a solution for infusion.

oral tablets prescribed in the study may include rmc-6291, daraxonrasib (rmc-6236) and rmc-9805. the tablets are taken according to the schedule defined by the study, typically once daily, with the exact dose determined by the investigators.

after the infusion, vital signs (blood pressure, pulse, temperature) are measured and laboratory tests are repeated to check for any immediate reactions.

you will be asked to report any side effects, such as nausea, fatigue, fever, or injection‑site reactions. these reports are recorded as adverse events.

treatment cycles are repeated according to the study schedule. each cycle includes the same intravenous infusion(s) of ivonescimab and any additional anti‑cancer agents, together with the prescribed oral tablets.

the dose and frequency of each medication remain as defined in the protocol, but may be modified by the investigators if safety concerns arise. dose adjustments are documented and communicated to you.

at predefined intervals (for example, every two or three cycles), additional laboratory tests and imaging examinations are performed to evaluate tumor response and monitor organ function.

the results are used to assess whether the disease is responding to treatment (objective response rate, disease control rate) and to detect any new safety issues.

treatment continues as long as the disease does not progress, side effects remain manageable, and the study protocol permits further administration.

if disease progression, unacceptable toxicity, or a decision by the investigator occurs, treatment is stopped.

when treatment ends, a final set of assessments is performed, including a complete physical examination, laboratory tests, and imaging to document the last disease status.

blood samples may be taken to measure serum concentrations of ivonescimab and to test for anti‑ivonescimab antibodies.

after the last dose, follow‑up visits are scheduled to monitor long‑term safety. during these visits, vital signs, laboratory tests and any late side effects are recorded.

the follow‑up period continues for a defined time after treatment, as specified by the study protocol.